Adaptimmune Therapeutics to Delist from Nasdaq by October 27

Adaptimmune Therapeutics ( (ADAP) ) has provided an update.

Adaptimmune Therapeutics announced its decision to voluntarily delist its American Depositary Shares from the Nasdaq Capital Market, effective after October 27, 2025, and to deregister under the Securities Exchange Act of 1934. This strategic move, following a transaction with US WorldMeds, aims to reduce costs and support the company’s focus on maximizing value from its remaining assets. The delisting will result in the suspension of filing obligations and may lead to trading on the OTC Pink Limited Market, though there are no guarantees of continued trading.

The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.

Spark’s Take on ADAP Stock

According to Spark, TipRanks’ AI Analyst, ADAP is a Neutral.

Adaptimmune Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and negative profitability. While technical indicators suggest some short-term bullish momentum, the negative P/E ratio and lack of dividend yield highlight valuation challenges. The absence of earnings call and corporate events data limits additional insights.

To see Spark’s full report on ADAP stock, click here.

More about Adaptimmune Therapeutics

Adaptimmune Therapeutics is a biopharmaceutical company focused on redefining the treatment of solid tumor cancers with cell therapies. The company has developed TECELRA, the first engineered T-cell therapy for solid tumor cancer approved in the U.S., and is exploring strategic options for its pre-clinical assets targeting PRAME and CD70.

Average Trading Volume: 98,303,580

Technical Sentiment Signal: Sell

Current Market Cap: $53.04M

See more data about ADAP stock on TipRanks’ Stock Analysis page.